Citations |
Biol Pharm Bull. 2022 Feb 3.<br/>ACS Nano. 2024 Jan 10.<br/>Int J Antimicrob Agents. 2019 Dec;54(6):814-819.<br/>ACS Nano. 2024 Jun 13.<br/>Adv Sci (Weinh). 2022 Oct 10;e2203831.<br/>Adv Sci (Weinh). 2023 Oct;10(28):e2302130.<br/>Arch Biochem Biophys. 2023 May 22, 109646.<br/>Biochem Bioph Res Co. 2020 Sep 10;530(1):292-300.<br/>Biochem Biophys Res Commun. 2024 Jun 15:725:150271.<br/>bioRxiv. 2023 Nov 5.<br/>Cancer Lett. 2022 Mar 9;215629.<br/>Carbohydr Polym. 2023 Jul 17, 121208.<br/>Cell Death Dis. 2022 Dec 16;13(12):1048.<br/>Cell Rep. 2021 Nov 2;37(5):109931.<br/>Environ Sci Technol. 2017 Dec 5;51(23):13938-13948.<br/>Eur J Pharmacol. 2022 Feb 11;920:174823.<br/>FASEB J. 2022 Jan;36(1):e22121.<br/>Int J Oncol. 2019 Jul;55(1):331-339.<br/>J Virol. 2021 Sep 22;JVI0153721.<br/>J Virol. 2023 Oct 17:e0107523.<br/>Mol Med Rep. 2019 Jan;19(1):41-50.<br/>Mol Pharm. 2024 May 9.<br/>Pharmaceuticals. 2022, 15(12), 1509<br/>Pharmacol Res. 2021 Dec 1;175:105985.<br/>PLoS Pathog. 2024 Feb 14;20(2):e1011981.<br/>Redox Biol. 2024 Apr:70:103064.<br/>Sci Adv. 2022 Nov 11;8(45):eabn6579.<br/>SSRN. 2023 Apr 10.<br/>Toxicol Appl Pharmacol. 2018 Oct 1;356:159-171. <br/>[1]Umezawa H, et al. Pepstatin, a new pepsin inhibitor produced by Actinomycetes. J Antibiot (Tokyo). 1970 May;23(5):259-62.<br/>[2]Seelmeier S, et al. Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A. Proc Natl Acad Sci U S A. 1988 Sep;85(18):6612-6. |
Product Description |
Pepstatin (Pepstatin A) Ammonium is a specific, orally active aspartic protease inhibitor produced by actinomycetes, with IC50s of 4.5 nM, 6.2 nM, 150 nM, 290 nM, 520 nM and 260 nM for hemoglobin-pepsin, hemoglobin-proctase, casein-pepsin, casein-proctase, casein-acid protease and hemoglobin-acid protease, respectively. Pepstatin Ammonium also inhibits HIV protease[1][2]. |
StorageTemperature |
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture) |